Abstracts tagged "Takayasu.s arteritis"

Abstract Number: 0707 • ACR Convergence 2023
Prevalence and Distribution of Vascular Calcifications at CT Scan in Patients with Large Vessel Vasculitis and Patients with Lymphoma: A Matched Cross-sectional Study
Chiara Marvisi¹, Giulia Besutti², Pamela Mancuso³, Roberto Farì⁴, Filippo Monelli⁴, Matteo Revelli⁴, Rexhep Durmo⁵, Elena Galli⁶, Francesco Muratore⁷, Lucia Spaggiari², Marta Ottone³, Stefano Luminari⁸, Pierpaolo Pattacini⁴, Paolo Giorgi Rossi³ and Carlo Salvarani⁹, ¹IRCCS di Reggio Emilia, Reggio Emilia, Italy, Reggio Emilia, Italy, ²IRCCS REGGIO EMILIA, Reggio Emilia, Italy, ³Epidemiology Unit, Azienda Unità Sanitaria Locale-IRCSS Reggio Emilia, Reggio Emilia, Italy, ⁴Radiology Unit, Azienda Unità Sanitaria Locale-IRCCS Reggio Emilia, Reggio Emilia, Italy, ⁵Nuclear Medicine Unit, Azienda Unità Sanitaria Locale-IRCSS Reggio Emilia, Reggio Emilia, Italy, ⁶Azienda Unità Sanitaria Locale-IRCCS Di Reggio Emilia, Reggio Emilia, Italy, ⁷IRCCS di Reggio Emilia, Reggio Emilia, Italy, ⁸Ematology Unit, Azienda Unità Sanitaria Locale-IRCCS Reggio Emilia, Reggio Emilia, Italy, ⁹Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy
Background/Purpose: Arterial wall calcifications are a hallmark of atherosclerosis and represent an important cardiovascular risk factor. Accelerated atherosclerosis and vascular calcifications have been reported in…
Abstract Number: 2604 • ACR Convergence 2023
Premature Vascular Smooth Muscle Cells Senescence Driven by Interleukin-6-Mitochondrial STAT3-Mitofusin 2 Signaling in Takayasu’s Arteritis
Chenglong Fang¹, Lihong Du¹, Lili Li², Yuexin Chen³, Zuoguan Chen⁴, Yongjun Li⁴, Jing Li¹, Mengtao Li⁵, xiaofeng Zeng⁶ and Xinping Tian⁵, ¹Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China, ²The State Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and School of Basic Medicine, Peking Union Medical College, Beijing, China, ³Department of Vascular Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China, ⁴Department of Vascular Surgery, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China, ⁵Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ⁶Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Background/Purpose: Takayasu’s arteritis (TAK) is characterized by persistent vascular inflammation involving aorta and its main branches, which is an important prosenescent factor that in turn…
Abstract Number: 1239 • ACR Convergence 2023
Clinical Manifestations and Management of Takayasu Arteritis: A Multicenter Pediatric Cohort
Ana Luiza Altaffer¹, Kristina Ciaglia², Elizabeth Sloan³ and Marietta De Guzman⁴, ¹Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²UT Southwestern and Scottish Rite for Children, Dallas, TX, ³UT Southwestern, Dallas, TX, ⁴Baylor College of Medicine, Houston, TX
Background/Purpose: Takayasu arteritis (TA) is a rare granulomatous vasculitis that affects large vessels, including the aorta, its major branches, and the pulmonary artery. Data on…
Abstract Number: 1352 • ACR Convergence 2023
Similar Delivery Outcomes in Pregnant Patients with and Without Takayasu Arteritis – A Nationwide Inpatient Database Study
Yanint Raksadawan¹, Aravind Polam¹, Nattanicha Chaisrimaneepan² and Sabahat Usmani¹, ¹Weiss Memorial Hospital, Chicago, IL, ²Texas Tech University Health Sciences, Lubbock, TX
Background/Purpose: Takayasu's arteritis (TA) is a large vessel vasculitis which affects women of reproductive age. There is limited information about the effect of TA on…
Abstract Number: 1567 • ACR Convergence 2023
Assessment of the Extent and Accrual of Damage in Takayasu’s Arteritis
Tanaz Kermani¹, SEMA KAYMAZ-TAHRA², David Cuthbertson³, Nader Khalidi⁴, Curry Koening⁵, Carol Langford⁶, Carol McAlear⁷, Paul Monach⁸, Larry Moreland⁹, Christian Pagnoux¹⁰, Philip Seo¹¹, Antoine G Sreih¹², Kenneth Warrington¹³, fatma Alibaz-Öner¹⁴, Haner Direskeneli¹⁵ and Peter Merkel⁷, ¹Rheumatology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, ²Sancaktepe Prof Dr Ilhan Varank Training and Research Hospital, Istanbul, Turkey, ³University of South Florida, Tampa, FL, ⁴McMaster University, Hamilton, ON, Canada, ⁵University of Texas Dell Medical School, Austin, TX, ⁶Cleveland Clinic, Cleveland, OH, ⁷University of Pennsylvania, Philadelphia, PA, ⁸VA Boston Healthcare System, Boston, MA, ⁹University of Colorado, Denver, CO, ¹⁰Mount Sinai Hospital, Toronto, ON, Canada, ¹¹Johns Hopkins University, Baltimore, MD, ¹²Bristol Myers Squibb, Princeton Pike, NJ, ¹³Mayo Clinic, Rochester, MN, ¹⁴Marmara University, School of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ¹⁵Division of Rheumatology, Medical School, Marmara University, Istanbul, Turkey
Background/Purpose: Damage is the irreversible consequence of disease or its treatment. This study aimed to evaluate the accrual of damage in Takayasu's arteritis (TAK) using…
Abstract Number: 1568 • ACR Convergence 2023
Comparison of Methotrexate and Azathioprine as the First Steroid-Sparing Immunosuppressive Agent in Patients with Takayasu’s Arteritis
Sema Kaymaz-Tahra¹, Ozun Bayindir Tsechelidis², Burak Ince³, Ozlem Ozdemir Isik⁴, Muhammet Emin Kutu⁵, Ozlem Karakas⁶, Tuba Demirci Yildirim⁷, Zeliha Ademoglu⁸, Elif Durak Ediboglu⁹, Burcu Ceren Ekti Uludogan¹⁰, Can Ilgin¹¹, Sule Yasar Bilge¹², Timucin Kasifoğlu¹², Servet Akar⁹, Hakan Emmungil⁸, Fatos Onen¹³, Ahmet Omma⁶, Nilufer Alpay Kanitez¹⁴, Ayten Yazici⁴, Ayse Cefle¹⁵, Murat Inanç¹⁶, Kenan Aksu¹⁷, Gökhan Keser¹⁷, Haner Direskeneli¹⁸ and fatma Alibaz-Öner¹⁹, ¹Sancaktepe Prof Dr Ilhan Varank Training and Research Hospital, Istanbul, Turkey, ²Ottawa University, Ottawa, ON, Canada, ³Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey, ⁴Kocaeli University Faculty of Medicine, Kocaeli, Turkey, ⁵Bakırkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey, ⁶Ankara City Hospital, Ankara, Turkey, ⁷Dokuz Eylul University, Izmir, Turkey, ⁸Trakya University Faculty of Medicine, Edirne, Turkey, ⁹Katip Celebi University Faculty of Medicine, Izmir, Turkey, ¹⁰Osmangazi University Faculty of Medicine, Eskişehir, Turkey, ¹¹Marmara University Faculty of Medicine, Istanbul, Turkey, ¹²Division of Rheumatology, Medical School, Osmangazi University, Eskişehir, Turkey, ¹³Division of Rheumatology, Dokuz Eylul University School of Medicine, Izmir, Turkey, ¹⁴Koc University Faculty of Medicine, Istanbul, Turkey, ¹⁵Division of Rheumatology, Medical School, Kocaeli University, Kocaeli, Turkey, ¹⁶Istanbul University, Istanbul, Turkey, ¹⁷Division of Rheumatology, Medical School, Ege University, Izmir, Turkey, ¹⁸Division of Rheumatology, Medical School, Marmara University, Istanbul, Turkey, ¹⁹Marmara University, School of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey
Background/Purpose: Conventional disease-modifying anti-rheumatic drugs (cDMARDs) are recommended in addition to glucocorticoids (GC) for all active Takayasu's arteritis (TAK) patients as the first-line therapy. However,…
Abstract Number: 1569 • ACR Convergence 2023
Efficacy and Safety of Tofacitinib and Tocilizumab in 84 Patients with Takayasu Arteritis: Single-Center Post-Hoc Analysis of a Prospective Study
Jing Li¹, Yang Zhao², Yang Yu³, Xianan Jian⁴, Yanhong Wang⁵, yunjiao yang⁶, Xinping Tian⁷, Mengtao Li⁷ and Xiaofeng Zeng⁷, ¹Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China, ²Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai, China, ³The Affiliated Hospital of Inner Mongolia Medical University, Huhhot, China, ⁴Puyang Oilfield General Hospital, Puyang, China, ⁵Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ⁶Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China, ⁷Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Background/Purpose: To compare the efficacy and safety of tofacitinib and tocilizumab in patients with Takayasu arteritis (TAK) in real world situation. Methods: A post-hoc analysis…
Abstract Number: 1570 • ACR Convergence 2023
Prognostic Assessment of the 2022 ACR/EULAR Classification Criteria for Takayasu Arteritis: A Multi-centre International Study
Emma Rinaldi¹, Corrado Campochiaro², Roberto Padoan³, Chengappa Kavadichanda⁴, Augustine Jose⁴, Kritika Singh⁵, Luca Iorio³, Naomi Viapiana⁶, Upendra Rathore⁵, Elena Marina Baldissera⁶, Vikas Agarwal⁵, Lorenzo Dagna⁷, Durga P Misra⁵ and Alessandro Tomelleri⁸, ¹Vita-Salute San Raffaele University, Milan, Italy, ²IRCCS San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Disease. Vita-Salute San Raffaele University, Milan, Italy, ³Department of Medicine DIMED, University of Padova, Padova, Italy, ⁴Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India, ⁵Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ⁶IRCCS San Raffaele Hospital, Milan, Italy, ⁷Ospedale San Raffaele, Milano, Italy, ⁸Unit of Immunology, Rheumatology, Allergy and Rare Diseases, San Raffaele Scientific Institute, Milano, Italy
Background/Purpose: The 2022 ACR/EULAR classification criteria for Takayasu arteritis (TAK) rely on a point-based clinical and imaging scoring system (from 0 to 22). The aim…
Abstract Number: 1571 • ACR Convergence 2023
Tocilizumab in Pregnant Takayasu Arteritis – The Use of Tocilizumab at Conception and Throughout Pregnancy in Those with Takayasu Arteritis
Nurul Aulia Zakaria¹, Andrew Porter², Robert Maughan², Charis Pericleous², Japna Satara³, Matthew Colquhoun⁴, Priyanka Agrawal³, jan Nouza³, Harold Wilson-Morkeh³, Taryn Youngstein² and Justin Mason², ¹National Heart & Lung Institute, Imperial College London, Kuantan, Malaysia, ²National Heart & Lung Institute, Imperial College London, London, United Kingdom, ³Rheumatology, Hammersmith Hospital, London, United Kingdom, ⁴Department of Rheumatology, Imperial College Healthcare Trust, London, United Kingdom
Background/Purpose: Takayasu arteritis (TA) is a large vessel vasculitis predominantly affecting female of reproductive age. Tocilizumab (TCZ) is frequently used in synthetic DMARD refractory cases.…
Abstract Number: 1573 • ACR Convergence 2023
Inpatient Prevalence and Comorbidity of Takayasu’s Arteritis: Nationwide Inpatient Sample 2016-2020
Husam el Sharu¹, Sukhvir Singh¹, Omar Alwahadneh², Mohammad Alqaisieh³ and Laksmi Subramanian¹, ¹East Carolina University, Greenville, NC, ²Carle Foundation Hospital, Urbana, IL, ³Hamilton Medical Center, Dalton, GA
Background/Purpose: Takayasu’s Arteritis (TAK) is a granulomatous large-vessel vasculitis that affects the aorta and its branches, and it is more commonly observed in women. We…
Abstract Number: 0215 • ACR Convergence 2023
Effectiveness of Three Doses of SARS-CoV-2 Vaccines in Brazilian Patients with Systemic Vasculitides: Preliminary Results of a Real-life Prospective Cohort
Erika Biegelmeyer¹, Mariana Freitas de Aguiar¹, Priscila Dias Cardoso Ribeiro¹, Ketty Lysie Libardi Lira Machado², Maria da Penha Gomes Gouveia², Camila Maria Paiva França Telles³, Samuel Elias Basualto Dias³, Natália Sarzi Sartori⁴, Thaís Evelyn Karnopp⁵, Vanessa de Oliveira Magalhães¹, Flávia Maria Matos Melo Campos Peixoto¹, Laiza Hombre Dias², Débora Marques Veghini², Rodrigo Vieira de Rezende⁶, Katia Lino Baptista⁶, Ana Karla Guedes de Melo⁷, Vitor Alves Cruz⁸, Maria Cecília Dias Corrêa⁹, Adriana Maria Kakehasi¹⁰, Rejane Maria Rodrigues de Abreu Vieira¹¹, Valderilio Feijó Azevedo¹², Olindo Assis Martins-Filho¹³, Charlles Heldan de Moura Castro¹, Ricardo Xavier¹⁴, Andréa Teixeira-Carvalho¹³, Viviane Angelina de Souza⁹, Odirlei André Monticelo¹⁵, Marcelo Pinheiro¹⁶, Edgard Torres dos Reis Neto¹, Emilia Sato¹, Gilda Ferreira¹⁷, Gecilmara Pileggi¹⁸, Valeria Valim¹⁹ and Alexandre wagner Silva de Souza²⁰, ¹Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil, ²Hospital Universitário Cassiano Antônio Moraes da Universidade Federal do Espírito Santo (HUCAM-UFES), Vitória, Brazil, ³Universidade Federal do Amazonas, Manaus, Brazil, ⁴Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ⁵Post-Graduate Program in Medical Sciences, School of Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ⁶Universidade Federal Fluminense, Niterói, Brazil, ⁷Hospital Universitário Lauro Wanderley, Universidade Federal da Paraíba, João Pessoa, Brazil, ⁸Universidade Federal de Goiás, Goiânia, Brazil, ⁹Universidade Federal de Juiz de Fora, Juiz de Fora, Brazil, ¹⁰Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil, ¹¹Universidade de Fortaleza (UNIFOR), Fortaleza, Brazil, ¹²Department of Internal Medicine, Hospital de Clínicas at the Federal University of Paraná, Curitiba, Paraná, Brazil, ¹³Instituto Renè Rachou, Fundação Oswaldo Cruz (FIOCRUZ-Minas), Belo Horizonte, Brazil, ¹⁴Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ¹⁵Division of Rheumatology, Department of Internal Medicine, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ¹⁶UNIFESP/ EPM, São Paulo, Brazil, ¹⁷Federal University of Minas Gerais, Belo Horizonte, Brazil, ¹⁸UNIFESP, Ribeirão Preto, Brazil, ¹⁹Universidade Federal do Espírito Santo, Vitória, Brazil, ²⁰Division of Rheumatology, Medical School, Universidade Federal de São Paulo, São Paulo, Brazil
Background/Purpose: Vaccine platforms, number of doses, and immunosuppressive drugs can influence the immunogenicity after SARS-CoV-2 vaccination in individuals with immune-mediated rheumatic diseases. Considering the heterogeneity…
Abstract Number: 1574 • ACR Convergence 2023
The Role of 18F-FDG PET/CT Scans in Takayasu Arteritis
Sahil Jain¹, Abdulrahman Khormi², Marcela Munoz-Urbano³, Shirish Sangle¹ and David D'Cruz⁴, ¹Louise Coote Lupus Unit, Guy's and St Thomas' Hospital NHS Foundation Trust, London, United Kingdom, ²Prince Sattam University Medical College, Al-Kharj, Saudi Arabia, ³Clínica Imbanaco, Cali, Colombia, ⁴Guy’s Hospital, Louise Coote Lupus Unit, London, United Kingdom
Background/Purpose: Takayasu arteritis (TA) is a large-vessel vasculitis which primarily affects the aorta and its main branches. Accurate assessment of disease activity has always been…
Abstract Number: 0695 • ACR Convergence 2023
Impact and Cardiovascular Outcomes of Large Vessel Vasculitis in Atrial Fibrillation Hospitalization: A Nationwide Inpatient Database Study
Sabahat Usmani¹, Yanint Raksadawan¹, Amro Taha¹, Harigopal Sandhyavenu¹, Jalpan Patel¹, Thatiana Schulze Goni¹, Hafiz Muhammad Waqar Younas¹ and Irisha Badu², ¹Weiss Memorial Hospital, Chicago, IL, ²Onslow Memorial Hospital, Jacksonville, FL
Background/Purpose: Atrial fibrillation is the most commonly treated cardiac arrhythmia, associated with significant morbidity and mortality. Recent research is suggestive that autoimmunity and inflammation might…
Abstract Number: 1575 • ACR Convergence 2023
Takayasu Arteritis Is Associated with Worse Fatigue Than Healthy Controls Which Persists over Time – A Longitudinal Cohort Study
Darpan Radheshyam Thakare, Upendra Rathore, Kritika Singh, Vikas Agarwal and Durga P Misra, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India
Background/Purpose: Few studies have assessed patient-reported outcome measures in Takayasu arteritis (TAK), a rare large vessel vasculitis. We prospectively analysed fatigue and fibromyalgia in TAK…
Abstract Number: 0696 • ACR Convergence 2023
Association of Large-vessel Vasculitis with Inflammatory Bowel Diseases: A European Case-control Study
Francois Maillet¹, Yann Nguyen², Olivier Espitia³, Laurent Perard⁴, Carlo Salvarani⁵, Etienne Rivière⁶, Cécile-Audrey Durel⁷, Philippe GUILPAIN⁸, Luc Mouthon⁹, Anna Kernder¹⁰, Javier Loricera¹¹, Pascal Cohen¹², Isabelle Melki¹³, Claire De Moreuil¹⁴, Nicolas Limal¹⁵, Arsène Mekinian¹⁶, Nathalie Costedoat-Chalumeau¹⁷, Nathalie Morel¹², Jonathan Boutemy¹⁸, Loic Raffray¹⁹, Jean-Sébastien Allain²⁰, Valerie Devauchelle²¹, Isabelle Kone-Paut²², Marc Fabre²³, Marie Durel²⁴, Antoine Dossier²⁵, Sébastien Abad²⁶, Marcella Visentini²⁷, Adrien Bigot²⁸, Halil Yildiz²⁹, Olivier Fain³⁰, Maxime Samson³¹, Guillaume Gondran³², Vered Abitbol¹ and Benjamin Terrier³³, ¹Cochin Hospital, Paris, France, ²Department of Internal Medicine, Hôpital Beaujon, AP-HP, Clichy, France., Montmorency, France, ³CHU de Nantes, Nantes, France, ⁴CH Saint Hoseph Saint Luc, Lyon, France, ⁵Azienda USL -IRCCS di Reggio Emilia and Università di Modena e Reggio Emilia, Reggio Emilia, Italy, ⁶CHU Bordeaux, Bordeaux, France, ⁷CHU Lyon, Lyon, France, ⁸University of Montpellier, Montpellier, France, ⁹Hopital Cochin - Paris University, Paris, France, ¹⁰HHU Düsseldorf, Düsseldorf, Germany, ¹¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹²CHU Cochin, Paris, France, ¹³Hopital Robert Debré, Sérurier, France, ¹⁴CHU de Brest, Brest, France, ¹⁵AP-HP, Créteil, France, ¹⁶Department of Internal Medicine, Hôpital Saint-Antoine, AP-HP, Paris, France, ¹⁷Inserm DR Paris 5, Paris, France, ¹⁸CHU de Caen, Caen, France, ¹⁹CHU la Réunion, La Réunion, France, ²⁰CHU Rennes, Rennes, France, ²¹UBO, Brest, France, ²²Department of Pediatric Rheumatology, Reference Centre for Autoinflammatory Disorders CEREMAIA, Bicêtre Hospital, APHP, University of Paris Saclay, Paris, France, ²³CH Bourgoin-Jallieu, Bourgoin-Jallieu, France, ²⁴CH Metz, Metz, France, ²⁵AP-HP, Paris, France, ²⁶Avicenne Hospital, Bobigny, France, ²⁷Rome Hospital, Rome, France, ²⁸Tours Hospital, Tours, France, ²⁹Saint Luc Hospital, Bruxelles, Belgium, ³⁰Hopital SAINT ANTOINE APHP, Paris, France, ³¹Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ³²Limoges Hospital, Limoges, France, ³³Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France
Background/Purpose: The association of large vessel vasculitis (LVV), whether Takayasu arteritis (TA) or giant cell arteritis (GCA), with inflammatory bowel disease (IBD) is a rare…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].